Clinical Trial: A Phase I Clinical Study to Evaluate the Safety of a 26-valent Pneumococcal Conjugate Vaccine in Individuals Aged 60 and Above

U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT06970756) titled 'A Phase I Clinical Study to Evaluate the Safety of a 26-valent Pneumococcal Conjugate Vaccine in Individuals Aged 60 and Above' on May 06.

Brief Summary: This Phase I, randomized, double-blind, parallel-controlled study is to be conducted in healthy adults aged 60 and above. Participants will be randomly assigned in a 1:1 ratio to receive either PCV26 or the comparator (PCV13) on Day 1 (Visit 1). Solicited AEs will be collected for 7 days post-vaccination and unsolicited AEs for 28 days post-vaccination, with safety data limited to SAEs, and NDCMCs collected up to 6 months post-vaccination.

Study Start Date: May 27

Study Type: INTE...